PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.92%
Revenue growth under 50% of 3088.T's 3.69%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
3.15%
Gross profit growth above 1.5x 3088.T's 1.57%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
32.84%
EBIT growth above 1.5x 3088.T's 17.70%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
28.75%
Operating income growth above 1.5x 3088.T's 17.71%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
25.93%
Net income growth 1.25-1.5x 3088.T's 22.41%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
25.93%
EPS growth similar to 3088.T's 24.28%. Walter Schloss would assume both have parallel share structures and profit trends.
25.93%
Similar diluted EPS growth to 3088.T's 24.28%. Walter Schloss might see standard sector or cyclical influences on both firms.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
142.00%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 122.80%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
46.86%
5Y revenue/share CAGR under 50% of 3088.T's 95.54%. Michael Burry would suspect a significant competitive gap or product weakness.
31.11%
3Y revenue/share CAGR 1.25-1.5x 3088.T's 23.45%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
182.37%
Below 50% of 3088.T's 391.34%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
44.64%
Below 50% of 3088.T's 182.32%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
51.81%
Positive short-term CAGR while 3088.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
304.14%
10Y equity/share CAGR 1.25-1.5x 3088.T's 246.01%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
79.56%
5Y equity/share CAGR at 50-75% of 3088.T's 135.26%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
35.29%
3Y equity/share CAGR above 1.5x 3088.T's 12.69%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
62.50%
3Y dividend/share CAGR of 62.50% while 3088.T is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-1.61%
Firm’s AR is declining while 3088.T shows 19.41%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-6.17%
Inventory is declining while 3088.T stands at 3.33%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-2.56%
Negative asset growth while 3088.T invests at 1.72%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
2.19%
50-75% of 3088.T's 3.04%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
11.12%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-1.84%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.